ArticleThe American journal of case reports2025
The Role of Laparoscopy in Diffuse Large B-Cell Lymphoma with High 18F-Fluorodeoxyglucose Uptake Lymph Node in the Retroperitoneum After Chemotherapy.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND In the management of diffuse large B-cell lymphoma (DLBCL), PET/CT imaging is routinely utilized after completion of 6-8 cycles of chemotherapy to assess therapeutic response. Lymph nodes displaying elevated 18F-Fluorodeoxyglucose (FDG) uptake on these scans frequently necessitate pathological verification or escalation of treatment intensity. While core-needle biopsy (CNB) is a widely used minimally invasive technique for lymph node sampling in superficial anatomical sites, its diagnostic yield for retroperitoneal lymph nodes remains suboptimal due to technical constraints, necessitating reliable diagnostic alternatives. Presently, standardized diagnostic algorithms are lacking for such metabolically active retroperitoneal lesions. CASE REPORT We prospectively evaluated 5 consecutive DLBCL patients with histologically confirmed diagnoses who completed 6-8 cycles of first-line immunochemotherapy. End-of-treatment PET/CT demonstrated metabolically active retroperitoneal lymph nodes (Deauville score 4-5) in all participants, meeting the criteria for equivocal treatment response. After excluding surgical contraindications, diagnostic laparoscopic retroperitoneal lymph node excision was performed under general anesthesia. The procedure successfully retrieved adequate tissue specimens from all targeted lesions, without intraoperative complications. Systematic histopathological evaluation incorporating immunohistochemical staining protocols was subsequently conducted on all specimens, revealing benign changes in 4 cases and residual lymphoma in 1 case. The resultant pathological profiles provided critical diagnostic clarity, directly informing subsequent therapeutic decision-making for each patient. CONCLUSIONS Laparoscopic lymph node excision constitutes a technically feasible and diagnostically robust approach for DLBCL patients with post-chemotherapy retroperitoneal FDG-avid lesions. This technique offers superior tissue acquisition capability compared to percutaneous biopsies, delivering essential pathological evidence to guide risk-adapted management strategies when conventional diagnostic modalities prove inconclusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.